Carlos A. Zarate mainly focuses on Antidepressant, Bipolar disorder, Major depressive disorder, Ketamine and Anesthesia. His studies deal with areas such as NMDA receptor, Antagonist, Mood disorders, Riluzole and Pharmacology as well as Antidepressant. His study in Bipolar disorder is interdisciplinary in nature, drawing from both Internal medicine and Lithium.
His Major depressive disorder study is concerned with the field of Depression as a whole. His Ketamine research is multidisciplinary, incorporating elements of Hydroxynorketamine, Bioinformatics, Major depressive episode, Electroconvulsive therapy and Dissociative. His study looks at the intersection of Anesthesia and topics like Randomized controlled trial with Lanicemine.
Carlos A. Zarate mostly deals with Major depressive disorder, Ketamine, Antidepressant, Bipolar disorder and Psychiatry. Carlos A. Zarate is exploring Major depressive disorder as part of his Depression and Neuroscience and Major depressive disorder studies. His Ketamine study is concerned with the larger field of Anesthesia.
His studies in Antidepressant integrate themes in fields like NMDA receptor, Pharmacology, Riluzole and Monoaminergic. Carlos A. Zarate interconnects Internal medicine, Lithium and Mood disorders in the investigation of issues within Bipolar disorder. In the field of Psychiatry, his study on Anxiety and Mood overlaps with subjects such as Suicidal ideation and Suicide prevention.
Ketamine, Antidepressant, Major depressive disorder, Depression and Pharmacology are his primary areas of study. His Ketamine study is within the categories of Anesthesia and Neuroscience. He combines subjects such as Metabotropic glutamate receptor, Glutamatergic, Long-term potentiation, Mood disorders and Monoaminergic with his study of Antidepressant.
His Major depressive disorder research incorporates themes from Bipolar disorder, Internal medicine, Crossover study and Rating scale. In general Depression study, his work on Esketamine often relates to the realm of Suicidal ideation, thereby connecting several areas of interest. His work investigates the relationship between Pharmacology and topics such as Hydroxynorketamine that intersect with problems in Pharmacokinetics and Metabotropic glutamate receptor 2.
Carlos A. Zarate focuses on Major depressive disorder, Ketamine, Antidepressant, Pharmacology and Crossover study. His Major depressive disorder study incorporates themes from Bipolar disorder, Internal medicine, Clinical psychology and Rating scale. His Ketamine study improves the overall literature in Anesthesia.
His Antidepressant study is concerned with Depression in general. His Depression research is under the purview of Psychiatry. His research in Pharmacology intersects with topics in NMDA receptor, Hydroxynorketamine, Psychotomimetic, Metabolite and Gamma power.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression
Carlos A. Zarate;Jaskaran B. Singh;Paul J. Carlson;Nancy E. Brutsche.
Archives of General Psychiatry (2006)
Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors
Sungho Maeng;Carlos A. Zarate;Jing Du;Robert J. Schloesser.
Biological Psychiatry (2008)
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Panos Zanos;Ruin Moaddel;Patrick J. Morris;Polymnia Georgiou.
Nature (2016)
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders
Gerard Sanacora;Carlos A. Zarate;John H. Krystal;Husseini K. Manji.
Nature Reviews Drug Discovery (2008)
A Randomized Add-on Trial of an N-methyl-d-aspartate Antagonist in Treatment-Resistant Bipolar Depression
Nancy Diazgranados;Lobna Ibrahim;Nancy E. Brutsche;Andrew Newberg.
Archives of General Psychiatry (2010)
Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial.
Carlos A. Zarate;Nancy E. Brutsche;Lobna Ibrahim;Jose Franco-Chaves.
Biological Psychiatry (2012)
Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression.
Husseini K Manji;Jorge A Quiroz;Jonathan Sporn;Jennifer L Payne.
Biological Psychiatry (2003)
The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders
Isabella Pacchiarotti;David J. Bond;Ross J. Baldessarini;Willem A. Nolen.
American Journal of Psychiatry (2013)
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Mauricio Tohen;Mauricio Tohen;K. N. Roy Chengappa;Trisha Suppes;Carlos A. Zarate.
Archives of General Psychiatry (2002)
The McLean-Harvard first-episode mania study: Prediction of recovery and first recurrence
Mauricio Tohen;Carlos A. Zarate;John Hennen;Hari Mandir Kaur Khalsa.
American Journal of Psychiatry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
National Institutes of Health
Johnson & Johnson (United States)
University of New Mexico
Janssen (Belgium)
Universidade de São Paulo
Icahn School of Medicine at Mount Sinai
National Institutes of Health
National University of Ireland, Galway
Stanford University
Delft University of Technology
Microsoft (United States)
Shifamed
Arizona State University
Zhejiang University of Technology
Radboud University Nijmegen
National Institutes of Health
University College London
Yale University
Advanced Cell Technology (United States)
University of Tsukuba
International Water Management Institute
University of Occupational and Environmental Health Japan
GlaxoSmithKline (United Kingdom)
University of Cambridge
University of Queensland